Thyroid Cancer Trial, Recruiting (NCT05510934)

Thyroid Cancer Trial, Recruiting NCT05510934 Sponsor: Nova Scotia Health Authority Condition: Thyroid Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05510934 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Thyroid Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults (over 18 years old) who are being seen at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC)
People with Stage 1 differentiated thyroid cancer (a specific type and stage of thyroid cancer) where there are no signs of cancer on scans or blood tests, including a very low level of a protein called thyroglobulin in the blood (below 0.06 mcg/L)
People with a low level of a specific antibody related to thyroid cancer (anti-thyroglobulin antibody below 20 IU/ml)
People whose thyroid ultrasound scan showed no signs of cancer returning, at least 24 months after their most recent treatment (for Stage 1 disease)
People with Stage 2 differentiated thyroid cancer where blood tests and scans show no signs of cancer, at least 48 months after their most recent treatment
People who are comfortable using a mobile phone app or a digital platform called Medable, and who have access to the internet

Who may not be able to join:

People who do not have an agreed and consented primary care provider (such as a regular family doctor or GP) on record

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Syed A. Imran, Dr., Nova Scotia Health

Phone: 902-473-2952

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05510934

Sponsor: Nova Scotia Health Authority

Phase: Not Applicable

Status: Recruiting

Condition: Thyroid Cancer

Trial contact: 902-473-2952

More information: https://clinicaltrials.gov/study/NCT05510934

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults (over 18 years old) who are being seen at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC)
People with Stage 1 differentiated thyroid cancer (a specific type and stage of thyroid cancer) where there are no signs of cancer on scans or blood tests, including a very low level of a protein called thyroglobulin in the blood (below 0.06 mcg/L)
People with a low level of a specific antibody related to thyroid cancer (anti-thyroglobulin antibody below 20 IU/ml)
People whose thyroid ultrasound scan showed no signs of cancer returning, at least 24 months after their most recent treatment (for Stage 1 disease)
People with Stage 2 differentiated thyroid cancer where blood tests and scans show no signs of cancer, at least 48 months after their most recent treatment
People who are comfortable using a mobile phone app or a digital platform called Medable, and who have access to the internet

Who may not be able to join:

People who do not have an agreed and consented primary care provider (such as a regular family doctor or GP) on record

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Nova Scotia Health Authority

Registry

ClinicalTrials.gov

Start date

30 September 2022

Est. completion

30 September 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Feasibility outcomes; DTC shared-care outcomes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov